Abstract
Familial Hypercholesterolemias (FH), well characterized from the genetic and clinical points of view, actually represent a “diagnostic problem” for the general practitioner.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Goldstein JL, Brown MS (1983). Familial Hypercholesterolemias. In; Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS (eds) Metabolic Basis of Inherited Diseases. Mc Graw-Hill BC, pag 675.
Van der Westhuyzen DR, Coetzee GA, Demasius IP, Harley EH, Gevers W, Baker SG, Seftel HC (1984). Low density lipoprotein receptor mutations in South African homozygous familial hypercholesterolemic patients. Arteriosclerosis, 4 (3), 238.
Mabuchi H, Ito S, Haba T, Ueda R, Tatami R, Kametami T, Koizumi J, Otha M, Miyamoto S, Takeda R, Takegoshi T (1977). Discrimination of familial hypercholesterolemia and secondary hypercholesterolemia by Achilles’ Tendon thickness. Atherosclerosis 28, 61.
Mol MJTM, Erkelens DW, Gevers Leuven JA, Schouten JA, Stalenhoef AFH (1986). Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolemias. Lancet ii, 936.
Durrington PN and Miller JP (1985). Double-blind, placebo-controlled, cross-over trial of Probucol in heterozygous familial hypercholesterolemias. Atherosclerosis 55, 187.
Descovich GC, Gaddi A, Mannino G, Lenzi S (1981). L’ indagine di Brisighella. I Fattori di Rischio Metabolici. Giorn It Cardiol 11, 1591.
National Research Council Atherosclerosis Research Group (1981). Atherosclerosis risk factors in nine italian population samples. Am J Epidemiol 11, 368.
Gaddi A, Lenzi S, Hagri GL, Sangiorgi Z, Descovich GC (1984). Improvement in the Mediteranean diet for hypercholesteremia correction using soy bean protein. In: Lenzi S, Descovich SC, (eds) “Atherosclerosis and Cardiovascular Diseases”. Lancaster-Boston-The Hague: MTP Press, 456.
National Research Council (1977). Laboratory Methods in Atherosclerosis Risk Factor Study. Ed. Dedalo, Ban, Vol I, pag 1.
Manual of Laboratory Operations, Lipid Research Clinic Programme: Lipid and Lipoprotein Analysis (1974). DHEW Public, no (NHI) 75, 628.
Lindgren FI, Jensen LC, Hacth FT (1972). The isolation and quantitative analysis of serum lipoproteins. In: Wilson G (ed) “Blood Lipids and Lipoproteins”, Wiley e Sons Inc, pag 181.
Mezzetti M, Gaddi A, Rimondi S, Descovich GC, Lenzi S (1987). Familial Hypercholesterolemias in Emilia-Romagna Region. In: Lenzi S, Descovich GC (eds): “Atherosclerosis and Cardiovascular Disesas prevention and therapy”. Ed. Compositori, Bologna, in press.
Simons LA, Balasubramaniam S, Holland J (1983). Low density lipoprotein metabolism in the normal to moderately elevated range of plasma cholesterol: comparisons with familial hypercholesterolemias. J Lipid Res 24, 192.
Habuchi HM, Sakai T, Sakay Y, Yoshimura A, Watanabe A, Wakasugi T, Koizumi J, Takeda R (1983). Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemias. New Engl J Med, 308, 609.
Malmendier CL, Delcroix C (1985). Effects of Fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis 85, 21.
Heldenberg D, Tamir I, Levtow O, Burnstein Y, Werbin B. (1979). Lipoprotein measurements - a necessity for precise assessment of risk in children from high risk families. Arch Dis Child 54, 695.
International Collaborative Study Group (1986). Metabolic epidemiology of plasma cholesterol. Mechanisms of variation of plasma cholesterol within populations and between populations. Lancet, ii, 991.
Vega GL, Grundy SM (1986). In vivo evidence for reduced binding of LDL to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest 78 (5), 1410.
Levy RA, Ostlund RE jr, Semenkovich CF, Witztum JL (1986). Diversity in expression of heterozygous familial hypercholesterolemia. Characterization of a unique kindred. J Clin Invest 78 (1), 96.
Hai-Jiang Cai (1985). Homozygous familial hypercholesterolemic patients in China. 7th Int Symp on Atherosclerosis, Melbourne, October 1985, (n’ 8).
Weisweiler P, Merk W, Jacob B, Schandt P (1985). Effect of combined treatment with Fenofibrate and Colestipol in familial hypercholesterolemias. 7th Int Symp on Atherosclerosis, Melbourne, October 1985, (n’ 453).
Yoshimura A, Wakasugi T, Nakayama A, Mabuchi H, Genda A, Takeda R (1985). Coronary angiographic characteristics in patients with familial hypercholesterolemias. 7th Int Symp on Atherosclerosis, Melbourne, October 1985, (n’ 37).
Glueck CJ, Tsang RC, Mellies MJ (1980). Long-term (2 to 6 yr) therapy of familial hypercholesterolemias and hypertriglyceridemias in childhood. In: Lauer RM, Shekelle RB (eds) “Childhood prevention of atherosclerosis and hypertension”, Raven Press, New York, pag 155.
Murphy EA and Kwiterovich PO (1977). Genetics of the hyperlipoproteinemias. In: Rifkind BM, Levy RI (eds) “Hyperlipidemia, diagnosis and theraphy”, Grune & Stratton, New York, pag 217.
Gaddi A, Sangiorgi Z, Perini P, Ghiselli G, Descovich GC (1987). Hypocholesterolemic effects of soy protein diet and apoprotein E isoforms. Eur Rew Med Pharmac Sci, in press.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 MTP Press Limited
About this chapter
Cite this chapter
Gaddi, A. et al. (1987). Familial hypercholesterolemia in Italy; plasma cholesterol evaluation and diagnostic insight. In: Lenzi, S., Descovich, G.C. (eds) Atherosclerosis and Cardiovascular Diseases. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-3205-0_36
Download citation
DOI: https://doi.org/10.1007/978-94-009-3205-0_36
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-7938-9
Online ISBN: 978-94-009-3205-0
eBook Packages: Springer Book Archive